Comparison of 68 Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer
Daniel Walacides, Astrid Meier, Anne Caroline Knöchelmann, Daniele Meinecke, Thorsten Derlin, Frank M. Bengel, Tobias L. Ross, Hans-Jürgen Wester, Katja Derlin, Markus A. Kuczyk, Christoph A. J. von Klot, Hans Christiansen, Christoph Henkenberens
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial
Andreas Hüttmann, Jan Rekowski, Stefan P. Müller, Bernd Hertenstein, Christiane Franzius, Rolf Mesters, Matthias Weckesser, Frank Kroschinsky, Jörg Kotzerke, Arnold Ganser, Frank M. Bengel, Paul La Rosée, Martin Freesmeyer, Heinz-Gert Höffkes, Andreas Hertel, Dirk Behringer, Gabriele Prange-Krex, Martin Griesshammer, Jens Holzinger, Stefan Wilop, Thomas Krohn, Aruna Raghavachar, Georg Maschmeyer, Ingo Brink, Roland Schroers, Tobias Gaska, Helga Bernhard, Aristoteles Giagounidis, Jochen Schütte, Ariane Dienst, Hubertus Hautzel, Ralph Naumann, Alfred Klein, Dennis Hahn, Gabriele Pöpperl, Matthias Grube, Jörg Marienhagen, Andreas Schwarzer, Lars Kurch, Thomas Höhler, Heike Steiniger, Holger Nückel, Thomas Südhoff, Wolfgang Römer, Marcus Brinkmann, Claudia Ose, Ferras Alashkar, Christine Schmitz, Jan Dürig, Dieter Hoelzer, Karl-Heinz Jöckel, Wolfram Klapper, Ulrich Dührsen
Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH‐HD2002 trial
L. Kurch, D. Hasenclever, R. Kluge, T. Georgi, L. Tchavdarova, M. Golombeck, O. Sabri, A. Eggert, W. Brenner, K.W. Sykora, F.M. Bengel, C. Rossig, D. Körholz, M. Schäfers, T. Feuchtinger, P. Bartenstein, R.A. Ammann, T. Krause, C. Urban, R. Aigner, S. Gattenlöhner, W. Klapper, C. Mauz‐Körholz
Load more…